Sonoma Pharmaceuticals, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Amy Trombly
- Full Time Employees
- 10
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 645 Molly Lane Woodstock GA United States of America 30189
- IPO Date
- Jan 25, 2007
- CIK
- 0001367083
- Website
- sonomapharma.com
- Similar Companies
- Business
- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) develops and commercializes stabilized hypochlorous acid (HOCl)-based products utilizing proprietary Microcyn Technology for applications including wound care, dermatological conditions, eye care, nasal care, oral care, podiatry and animal health care. The company offers a range of prescription, over-the-counter (OTC) and office-dispense products such as Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel, Microcyn wound and skin care solutions, Acuicyn Eyelid and Eyelash Hygiene, Ocucyn Eyelid and Eyelash Cleanser and MicrocynAH for animal wounds and infections; these products provide anti-inflammatory, regenerative and antimicrobial benefits by reducing infections, itch, pain and scarring. Sonoma Pharmaceuticals operates globally in the United States, Europe, Asia, Latin America and other international markets, with manufacturing in the United States and Latin America, European marketing headquartered in Roermond, Netherlands, and corporate headquarters in Boulder, Colorado following a recent relocation from Woodstock, Georgia. Founded in 1999 as Micromed Laboratories Inc. in Petaluma, California, the company pioneered stable HOCl formulations, launching Microcyn Wound Care in 2004, evolving through name changes including Oculus Innovative Sciences in 2001 and adopting its current name in 2016. Sonoma targets healthcare professionals, consumers and veterinary markets with medical device-classified solutions focused on chronic skin conditions, acute and chronic wounds, burns and infections. In recent developments, Sonoma entered a Master Supply Agreement with WellSpring Pharmaceutical Corporation on January 29, 2025, to expand consumer healthcare distribution in the United States, and formed alliances with Medline, LP to enhance U.S. sales; additionally, in October 2024, the company announced an expanded partnership with a global healthcare distributor for wound care product distribution in Canada, including OTC accessibility. These strategic moves support rising revenues and new product initiatives amid growth in skin health and antimicrobial demand, with third fiscal quarter 2025 results reflecting positive operational cash flow. The company continues to pursue funding opportunities through partnerships and equity offerings to fuel global expansion.
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update
Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering
Sonoma Pharmaceuticals (SNOA) Jumps 16% After Hours On Burn Relief Hydrogel Launch In Walmart, CVS
Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart
Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
Head to Head Comparison: Ocular Therapeutix (NASDAQ:OCUL) & Sonoma Pharmaceuticals (NASDAQ:SNOA)
Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above 200-Day Moving Average – Time to Sell?
National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results
Sonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. Hospitals
Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA
Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock
Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial Results
Sonoma Pharmaceuticals (SNOA) Is Attractively Priced Despite Fast-paced Momentum